Determination of a peptide-doxorubicin, prostate-specific antigen activated prodrug, and its active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection - Stabilization of the peptide prodrug with EDTA

被引:5
作者
Schwartz, MS [1 ]
Matuszewski, BK [1 ]
机构
[1] Merck & Co Inc, Merck Res Labs, W Point, PA 19486 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 780卷 / 01期
关键词
peptide-doxorubicin; doxorubicin; leucine-doxorubicin;
D O I
10.1016/S1570-0232(02)00464-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A method for the determination of I, a peptide-doxorubicin conjugate that was evaluated for the treatment of prostate cancer, and two of its active metabolites, doxorubicin and leucine-doxorubicin is described. Blood samples were chilled immediately after being drawn in order to prevent ex vivo entry of the metabolites into red blood cells. EDTA (10 mg/ml final concentration) was used to prevent plasma-mediated degradation of the peptide portion of the prodrug. After the addition of internal standard, plasma was prepared for analysis using a C-8 solid-phase extraction column. In order to overcome secondary ionic interactions with the silica-based extraction column, the analytes were eluted with ammonium hydroxide in methanol. The extracts were evaporated to dryness, reconstituted, and assayed by step change, gradient, reverse phase HPLC with fluorescence detection. Two interfering metabolites found in post dose plasma were chromatographically separated by an adjustment of the mobile phase pH. The within-day reproducibility of the doxorubicin and leucine-doxorubicin chromatographic retention times was improved by a brief washing of the analytical column with 90% acetonitrile after each injection. The range of the standard curve was 12.5-1250 ng/ml for doxorubicin and 25-2500 ng/ml for I and leucine-doxorubicin. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:171 / 182
页数:12
相关论文
共 6 条
[1]   A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo [J].
DeFeo-Jones, D ;
Garsky, VM ;
Wong, BK ;
Feng, DM ;
Bolyar, T ;
Haskell, K ;
Kiefer, DM ;
Leander, K ;
McAvoy, E ;
Lumma, P ;
Wai, J ;
Senderak, ET ;
Motzel, SL ;
Keenan, K ;
Van Zwieten, M ;
Lin, JH ;
Freidinger, R ;
Huff, J ;
Oliff, A ;
Jones, RE .
NATURE MEDICINE, 2000, 6 (11) :1248-1252
[2]   FULLY AUTOMATED-DETERMINATION OF A NEW ANTHRACYCLINE N-L-LEUCYLDOXORUBICIN AND 6 METABOLITES IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ONLINE SAMPLE HANDLING [J].
DEJONG, J ;
MUNNIKSMA, CN ;
GUERAND, WS ;
BAST, A ;
VANDERVIJGH, WJF .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 574 (02) :273-281
[3]  
DIPAOLA RS, 2002, IN PRESS J CLIN ONCO
[4]   PROSTATE-SPECIFIC ANTIGEN EXPRESSION BY VARIOUS TUMORS [J].
LEVESQUE, M ;
HU, H ;
DCOSTA, M ;
DIAMANDIS, EP .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1995, 9 (02) :123-128
[5]   N-SUBSTITUTED 1-CYANOBENZ[F]ISOINDOLE - EVALUATION OF FLUORESCENCE EFFICIENCIES OF A NEW FLUOROGENIC LABEL FOR PRIMARY AMINES AND AMINO-ACIDS [J].
MATUSZEWSKI, BK ;
GIVENS, RS ;
SRINIVASACHAR, K ;
CARLSON, RG ;
HIGUCHI, T .
ANALYTICAL CHEMISTRY, 1987, 59 (08) :1102-1105
[6]  
Stewart A K, 2000, CA Cancer J Clin, V50, P171, DOI 10.3322/canjclin.50.3.171